This is a request for anyone who works for, or knows someone who works for Ciba Geigy or perhaps someone in an academic setting who can request data to try and find out why desoxypipradrol was dropped by Ciba Geigy Pharma following human trials in 1958-9
The historywas that Merrell now part of Aventis patented 1952 or thereabouts and ran with pipradrol, which was rather successfull.
Ciba Geigy held the patent for desoxypipradrol and given the success of piradrol they initiated trials, these trials went as far as human trials and even came up with 1 and 2 mg tablet formulations. then the trials were then stopped and the product never made it to market.
Schering also carried out trials of various diphenylmethylpiperidines which were substituted with hydroxy groups on the piperidine ring and some with hydroxyethyl group on the nitrogen,none of these made it to market either.
the isomeric 4-(diphenylmethyl)piperidine (desoxypiradrol with the diphenyl methyl group moved opposite the nitrogen) has potent toxic effects on the islet cells in the pancreas, apparently the 2-(diphenylmethyl)piperidine (desoxypipradrol) does not have these effects so I don't thnk this is the reason.
perhaps the long duration of action or idiosyncratic reactions were the reason?
In the interests of harm reduction it would be nice to know what they discovered 40 years ago hence this request.
I'm no guinea pig but I am rather interested in desoxypipradrol.
forewarned is forearmed
V
The historywas that Merrell now part of Aventis patented 1952 or thereabouts and ran with pipradrol, which was rather successfull.
Ciba Geigy held the patent for desoxypipradrol and given the success of piradrol they initiated trials, these trials went as far as human trials and even came up with 1 and 2 mg tablet formulations. then the trials were then stopped and the product never made it to market.
Schering also carried out trials of various diphenylmethylpiperidines which were substituted with hydroxy groups on the piperidine ring and some with hydroxyethyl group on the nitrogen,none of these made it to market either.
the isomeric 4-(diphenylmethyl)piperidine (desoxypiradrol with the diphenyl methyl group moved opposite the nitrogen) has potent toxic effects on the islet cells in the pancreas, apparently the 2-(diphenylmethyl)piperidine (desoxypipradrol) does not have these effects so I don't thnk this is the reason.
perhaps the long duration of action or idiosyncratic reactions were the reason?
In the interests of harm reduction it would be nice to know what they discovered 40 years ago hence this request.
I'm no guinea pig but I am rather interested in desoxypipradrol.
forewarned is forearmed
V

,May i ask where you got your info. on the human trials, if it made it to phase 3, it must of been documented somewhere,I can't find it anywhere on the internet